ReviewJournal of immunology research2014
Role of microbiota and innate immunity in recurrent Clostridium difficile infection.
Review in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Gastrointestinal surgery and the gut microbiome: a systematic literature review.European journal of clinical nutrition · 2021Pooled it
- Clostridioides difficile infection among patients with type 2 diabetes mellitus.Internal and emergency medicine · 2026Article
- Review
- The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.Cancers · 2025Review
- Review
- Clostridium difficile infection following colon subtotal resection in a patient with gallstones: A case report and review of literature.World journal of gastrointestinal surgery · 2024Article
- Two Doses of Zn Induced Different Microbiota Profiles and Dietary Zinc Supplementation Affects the Intestinal Microbial Profile, Intestinal Microarchitecture and Immune Response in Pigeons.Animals : an open access journal from MDPI · 2024Article
- Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0.Advances in experimental medicine and biology · 2024Review
- Gut microbiota and immunotherapy of renal cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Is there a role for microbiome-based approach in common variable immunodeficiency?Clinical and experimental medicine · 2023Review
- Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota.Nutrients · 2023Review
- 16S rRNA Gene Amplicon Sequencing of Gut Microbiota Affected by Four Probiotic Strains in Mice.Veterinary sciences · 2023Article
- Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy.Biomedicines · 2023Review
- Impact of Diet on Gut Microbiota Composition and Microbiota-Associated Functions in Heart Failure: A Systematic Review of In Vivo Animal Studies.Metabolites · 2022Review
- Risk Factors, Diagnosis, and Management ofMicroorganisms · 2022Review
- Alterations of Gut Microbiota by Overnutrition Impact Gluconeogenic Gene Expression and Insulin Signaling.International journal of molecular sciences · 2021Review
- Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor.Journal of clinical medicine · 2020Review
- Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2.The Journal of experimental medicine · 2020Article
- News Feature: Editing the microbiome.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Probiotic Supplementation in aMicroorganisms · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent Clostridium difficile infection represents a burdensome clinical issue whose epidemiology is increasing worldwide. The pathogenesis is not yet completely known. Recent observations suggest that the alteration of the intestinal microbiota and impaired innate immunity may play a leading role in the development of recurrent infection. Various factors can cause dysbiosis. The causes most involved in the process are antibiotics, NSAIDs, acid suppressing therapies, and age. Gut microbiota impairment can favor Clostridium difficile infection through several mechanisms, such as the alteration of fermentative metabolism (especially SCFAs), the alteration of bile acid metabolism, and the imbalance of antimicrobial substances production. These factors alter the intestinal homeostasis promoting the development of an ecological niche for Clostridium difficile and of the modulation of immune response. Moreover, the intestinal dysbiosis can promote a proinflammatory environment, whereas Clostridium difficile itself modulates the innate immunity through both toxin-dependent and toxin-independent mechanisms. In this narrative review, we discuss how the intestinal microbiota modifications and the modulation of innate immune response can lead to and exacerbate Clostridium difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.